Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5093324
Max Phase: Preclinical
Molecular Formula: C40H71N11O14
Molecular Weight: 930.07
Molecule Type: Unknown
Associated Items:
ID: ALA5093324
Max Phase: Preclinical
Molecular Formula: C40H71N11O14
Molecular Weight: 930.07
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(C)=O)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(N)=O
Standard InChI: InChI=1S/C40H71N11O14/c1-11-19(6)30(39(64)45-24(33(42)58)14-28(41)56)50-37(62)27(16-52)48-36(61)25(12-17(2)3)46-35(60)26(13-18(4)5)47-40(65)32(22(9)54)49-29(57)15-43-38(63)31(21(8)53)51-34(59)20(7)44-23(10)55/h17-22,24-27,30-32,52-54H,11-16H2,1-10H3,(H2,41,56)(H2,42,58)(H,43,63)(H,44,55)(H,45,64)(H,46,60)(H,47,65)(H,48,61)(H,49,57)(H,50,62)(H,51,59)/t19-,20-,21+,22+,24-,25-,26-,27-,30-,31-,32-/m0/s1
Standard InChI Key: MSKIZGRQXUUASB-YDTYMFDWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 930.07 | Molecular Weight (Monoisotopic): 929.5182 | AlogP: -5.73 | #Rotatable Bonds: 29 |
Polar Surface Area: 408.77 | Molecular Species: NEUTRAL | HBA: 14 | HBD: 14 |
#RO5 Violations: 3 | HBA (Lipinski): 25 | HBD (Lipinski): 16 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.33 | CX Basic pKa: | CX LogP: -6.34 | CX LogD: -6.34 |
Aromatic Rings: 0 | Heavy Atoms: 65 | QED Weighted: 0.03 | Np Likeness Score: 0.00 |
1. Lior Y, Shtriker E, Kahremany S, Lewis EC, Gruzman A.. (2022) Development of anti-inflammatory peptidomimetics based on the structure of human alpha1-antitrypsin., 228 [PMID:34763945] [10.1016/j.ejmech.2021.113969] |
Source(1):